Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMU8ANS)

Drug Name
Ximelegatran Drug Info
Synonyms
Cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; y-27632; 146986-50-7; Y-27632 dihydrochloride; Y27632; UNII-0X370ROP6H; Y 27632; cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-4-pyridinyl-, trans-; 0X370ROP6H; CHEBI:75393; 4-[(1R)-1-aminoethyl]-N-(pyridin-4-yl)cyclohexane-1-carboxamide; (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4-[(1R)-1-aminoethyl]-N-(4-pyridyl)cyclohexanecarboxamide; 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide; (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide; Y-27632
Cross-matching ID
PubChem CID
448042
ChEBI ID
CHEMBL75393
CAS Number
CAS 146986-50-7
TTD Drug ID
D0B5LF
VARIDT Drug ID
DR00750

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.70 0.00e+0 34/36 (94.44%) POLE2;MCM2;MCM4;...
Fanconi anemia pathway 2.23 0.00e+0 36/54 (66.67%) RAD51;FANCL;BRCA1;...
Homologous recombination 2.22 0.00e+0 35/41 (85.37%) RAD54B;RAD51;BRCA1;...
Cell cycle 2.21 0.00e+0 110/124 (88.71%) PLK1;CDC20;CCNE2;...
Mismatch repair 2.06 0.00e+0 22/23 (95.65%) MSH2;LIG1;RFC5;...
Base excision repair 2.05 0.00e+0 29/33 (87.88%) POLE2;FEN1;LIG1;...
Nucleotide excision repair 2.03 0.00e+0 40/47 (85.11%) POLE2;LIG1;RFC5;...
Spliceosome 2.02 0.00e+0 101/150 (67.33%) LSM7;LSM3;HSPA8;...
Pyrimidine metabolism 1.94 5.79e-4 40/56 (71.43%) DPYD;CAD;TYMS;...
Ribosome biogenesis in eukaryotes 1.80 6.25e-3 52/108 (48.15%) POP5;NOP56;FBL;...
Ribosome 1.74 1.28e-2 113/158 (71.52%) MRPL12;RPS5;MRPL4;...
N-Glycan biosynthesis 1.71 1.48e-2 38/50 (76%) ST6GAL1;ALG8;DPAGT1;...
Aminoacyl-tRNA biosynthesis 1.70 1.48e-2 15/66 (22.73%) QRSL1;DARS2;TARS2;...
Oocyte meiosis 1.62 3.12e-2 90/129 (69.77%) PLK1;CDC20;CCNE2;...
Progesterone-mediated oocyte maturation 1.62 2.92e-2 75/100 (75%) PLK1;CDC25B;CCNB1;...
Proteasome 1.60 3.22e-2 44/46 (95.65%) PSMD3;PSMA3;PSMC6;...
alpha-Linolenic acid metabolism -1.79 8.72e-3 17/25 (68%) PLA2G2D;PLA2G6;PLA2G2F;...
Hematopoietic cell lineage -1.79 8.98e-3 90/99 (90.91%) CD19;IL4;CD3G;...
Lipid and atherosclerosis -1.80 9.25e-3 190/215 (88.37%) NCF4;PPP3CB;EIF2AK3;...
Autophagy -1.81 8.95e-3 113/169 (66.86%) IGF1R;AKT3;PPP2CB;...
Human cytomegalovirus infection -1.82 8.32e-3 201/225 (89.33%) CALML4;SOS2;GNB5;...
Natural killer cell mediated cytotoxicity -1.82 8.61e-3 99/131 (75.57%) SOS2;CD244;FYN;...
Viral myocarditis -1.82 8.92e-3 53/60 (88.33%) HLA-A;ABL2;MYH7;...
Autoimmune thyroid disease -1.82 9.25e-3 46/53 (86.79%) CTLA4;TG;HLA-DQA1;...
Th17 cell differentiation -1.83 9.43e-3 95/107 (88.79%) PPP3CB;SMAD4;JAK1;...
Prostate cancer -1.85 8.59e-3 93/97 (95.88%) CREB5;PIK3CD;NFKB1;...
Endocytosis -1.86 7.63e-3 198/252 (78.57%) HLA-A;IGF1R;IQSEC1;...
Lysosome -1.88 8.03e-3 115/128 (89.84%) AP3D1;FUCA1;TCIRG1;...
MAPK signaling pathway -1.89 7.71e-3 272/294 (92.52%) EFNA4;MAP2K3;NFKB2;...
Shigellosis -1.89 8.16e-3 180/246 (73.17%) RRAGA;CYTH4;MYL12B;...
Cocaine addiction -1.91 6.94e-3 42/49 (85.71%) GRIN2C;GRIA2;CREB5;...
NF-kappa B signaling pathway -1.93 6.47e-3 90/104 (86.54%) TRIM25;GADD45G;MYD88;...
Allograft rejection -1.95 4.95e-3 32/38 (84.21%) IL4;CD86;HLA-DPB1;...
C-type lectin receptor signaling pathway -1.97 3.20e-3 93/104 (89.42%) PIK3CD;PTPN11;NFKB1;...
Proteoglycans in cancer -1.98 2.31e-3 172/205 (83.9%) ITGB3;SDC2;ITGA2;...
Salmonella infection -1.99 1.26e-3 198/249 (79.52%) DCTN2;ELMO2;PTPRC;...
Osteoclast differentiation -2.01 0.00e+0 117/127 (92.13%) CYLD;NCF4;FYN;...
Graft-versus-host disease -2.01 0.00e+0 32/42 (76.19%) CD86;HLA-DPB1;HLA-A;...
Th1 and Th2 cell differentiation -2.02 0.00e+0 80/92 (86.96%) JAK1;CD4;NFKB1;...
Bladder cancer -2.08 0.00e+0 40/41 (97.56%) E2F2;MAPK1;EGFR;...
Pathogenic Escherichia coli infection -2.09 0.00e+0 152/197 (77.16%) PTPN11;ARPC2;NFKB1;...
Kaposi sarcoma-associated herpesvirus infection -2.11 0.00e+0 172/193 (89.12%) HLA-E;LYN;UBC;...
Phagosome -2.13 0.00e+0 118/152 (77.63%) ITGB3;DYNC1LI1;ITGA2;...
Rheumatoid arthritis -2.14 0.00e+0 78/93 (83.87%) ATP6V1A;TCIRG1;TEK;...
Epithelial cell signaling in Helicobacter pylori infect... -2.18 0.00e+0 62/70 (88.57%) TJP1;ATP6V1A;TCIRG1;...
Mitophagy -2.27 0.00e+0 56/68 (82.35%) USP8;CSNK2A2;TFE3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 4uM 6H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.08uM - 20uM 6H, 24H, 48H
Bone marrow
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.08uM - 10uM 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.08uM - 10uM 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.08uM - 10uM 6H, 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 4uM 6H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 4uM 6H
MDST8 CVCL_1400 Homo sapiens 4uM 6H
NCI-H508 CVCL_1561 Homo sapiens 4uM 6H
SNU-1040 CVCL_5001 Homo sapiens 4uM 6H
SNU-C4 CVCL_5008 Homo sapiens 4uM 6H
SNU-C5 CVCL_5009 Homo sapiens 4uM 6H
SW480 CVCL_0546 Homo sapiens 4uM 6H
SW620 CVCL_0547 Homo sapiens 4uM 6H
SW948 CVCL_0550 Homo sapiens 4uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 4uM 6H
HT115 CVCL_1294 Homo sapiens 4uM 6H
RKO CVCL_0504 Homo sapiens 4uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 4uM 6H
SNG-M CVCL_1707 Homo sapiens 4uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 4uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
A549/Asc-1 CVCL_YA87 Homo sapiens 0.04uM - 10uM 24H
DV-90 CVCL_1184 Homo sapiens 4uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 4uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 4uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 4uM 6H
T3M-10 CVCL_1729 Homo sapiens 4uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 4uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 4uM 6H
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 4uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 4uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 4uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 4uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 4uM 6H
OV7 CVCL_1623 Homo sapiens 4uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 4uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 4uM 6H
RMUG-S CVCL_1666 Homo sapiens 4uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 4uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 6H, 24H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 4uM 6H
PL-21 CVCL_2161 Homo sapiens 4uM 6H
SKM-1 CVCL_0010 Homo sapiens 4uM 6H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 4uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 4uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
SK-L CVCL_1699 Homo sapiens 0.04uM - 10uM 24H
SK-MEL-1 CVCL_0523 Homo sapiens 4uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 4uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 4uM 6H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H